Micro Market Research
US/CAN Toll Free

You are here :   Home     Healthcare     Pharmaceuticals     Drug formulations     ATC     Antiinfectives for Systemic Use     Vaccines     Animal Vaccines     Recombinant vaccines    
Real Time Market Research & Industry Analysis - MicroMarketMonitor

European Recombinant vaccines Market Research Report

  • Report Code: RE 1001
  • Publish Date: Upcoming
Table of Contents
Customer Intelligence
Inquiry Before Buying Ask for Discount

The European Recombinant Animal Vaccine Market is mainly driven by new opportunities in emerging diseases related to poultry facilities and increasing incidences of zoonotic diseases in humans. This market was valued at $140.2 million in 2013 and is expected to reach $190 million by 2018, at a CAGR of 6.3%.


 “The European Recombinant Animal Vaccine Market, 2012-2018” analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry.


All these products have experienced a positive growth with an increased awareness for procedures and sophisticated diagnostic techniques. Recombinant vaccines offer various advantages over traditional vaccines, such as no post-vaccination reactions and they are safe as there is no risk of contracting a disease from the agent. An additional advantage of this vaccine is that it does not need an adjuvant. Some adjuvants are known to cause cancer in some animals over time.


Numerous recombinant vaccines have recently entered the poultry market. The recently launched INNOVAX, a line of recombinant vaccines, includes products such as INNOVAX-ND, INNOVAX-ND-SB, INNOVAX-ILT, and INNOVAX-ILT-SB.


Europe is the fastest growing market owing to highly organized livestock sector. This growth is attributed to the highly organized livestock farms and the huge demand for livestock products, such as food (meat, egg, milk, and its byproducts) and non-food items from the European population. The demand for livestock products is high in European countries For example, beef imports in the European Union (EU) increased by 5% from 2012 to 2013 to the total of 187,974 tones.


The report also provides an extensive competitive landscaping of companies operating in this market. The main companies are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac.


 Segment and country specific Company shares, News & Deals, M&A, segment specific pipeline products, product approvals and product recalls of the major companies have been detailed.



Customization Options:

Along with the market data, you can also customize MMM assessments that meet your Company’s specific needs. Customize to get comprehensive industry standards and deep dive analysis of the following parameters:


Product Analysis

  • Usage pattern (in-depth trend analysis) of products (Segment wise)
  • Product Matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub segment level
  • End-user Adoption rate analysis of the products (Segment wise and Country wise)
  • Comprehensive coverage of Product approvals, Pipeline products and Product recalls


Epidemiology Data

  • Country specific Prevalence of Mareks disease, Newcastle disease and fowl laryngotracheitis.
  •  Country specific Patient pool of Mareks disease, Newcastle disease and fowl laryngotracheitis.
  • Disease progression (Pattern analysis)


Surgeons/Physicians Perception Analysis

  • Fast turn-around analysis of Surgeons response to market events and trends
  • Pattern analysis of usage of Recombinant vaccines by Physicians
  • Surgeons’ opinion about products from different companies
  • Surgeons’ qualitative inputs on epidemiology data


Brand/ Product Perception Matrix

  • Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
  • Analysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)


Competitive Intelligence

  • The company share analysis of Recombinant Animal Vaccine Market for the top players of the market in Europe.
  • The crucial developments and strategies of companies inculcating in their portfolio for Recombinant Animal Vaccine Market




1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)
2 Executive Summary
3 Market Overview
4 Recombinant vaccines-Europe, By Types
4.1 Split By Geography
4.1 Recombinant vaccines-United Kingdom by Types
4.1 Recombinant vaccines-Germany by Types
4.1 Recombinant vaccines-France by Types
4.1 Recombinant vaccines-Italy by Types
4.1 Recombinant vaccines-Spain by Types
4.1 Recombinant vaccines-Europe - Other Geographies by Types
4.2 Recombinant vaccines-Preventive-Europe
4.2.1 Recombinant vaccines-Preventive-Europe, By Geographies Recombinant vaccines-Preventive-United Kingdom Recombinant vaccines-Preventive-France Recombinant vaccines-Preventive-Germany Recombinant vaccines-Preventive-Italy Recombinant vaccines-Preventive-Spain Recombinant vaccines-Preventive-Europe - Other Geographies
4.3 Recombinant vaccines-Therapeutic-Europe
4.3.1 Recombinant vaccines-Therapeutic-Europe, By Geographies Recombinant vaccines-Therapeutic-United Kingdom Recombinant vaccines-Therapeutic-France Recombinant vaccines-Therapeutic-Germany Recombinant vaccines-Therapeutic-Italy Recombinant vaccines-Therapeutic-Spain Recombinant vaccines-Therapeutic-Europe - Other Geographies
5 Recombinant vaccines-Europe, By Geographies
5.1 Recombinant vaccines-United Kingdom
5.1.1 Recombinant vaccines-United Kingdom, By Types Recombinant vaccines-Preventive-United Kingdom Recombinant vaccines-Therapeutic-United Kingdom
5.2 Recombinant vaccines-Germany
5.2.1 Recombinant vaccines-Germany, By Types Recombinant vaccines-Preventive-Germany Recombinant vaccines-Therapeutic-Germany
5.3 Recombinant vaccines-France
5.3.1 Recombinant vaccines-France, By Types Recombinant vaccines-Preventive-France Recombinant vaccines-Therapeutic-France
5.4 Recombinant vaccines-Italy
5.4.1 Recombinant vaccines-Italy, By Types Recombinant vaccines-Preventive-Italy Recombinant vaccines-Therapeutic-Italy
5.5 Recombinant vaccines-Spain
5.5.1 Recombinant vaccines-Spain, By Types Recombinant vaccines-Preventive-Spain Recombinant vaccines-Therapeutic-Spain
5.6 Recombinant vaccines-Europe - Other Geographies
5.6.1 Recombinant vaccines-Europe - Other Geographies, By Types Recombinant vaccines-Preventive-Europe - Other Geographies Recombinant vaccines-Therapeutic-Europe - Other Geographies

Please fill in the form below to receive a free copy of the Summary of this Report

European Recombinant vaccines Market Research Report

* Enter the text from the image to the text box :

refresh captcha
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
Connect With Us
US/CAN : +1-888-502-0539